16 September 2026

Market Announcements Office
ASX Limited
Level 27, 39 Martin Place, Sydney NSW

Dear Sir/Madam,

**Re: Late Lodgement of Notices of Change of Interests of Substantial Shareholders**

We refer to the attached Notices of Change of Interests of Substantial Shareholders for the following in respect of holdings in Cambium Holdings Limited (ASX: CMB):

- Zheng Yang Biomedical Technology Co, Ltd (ZYBT);
- Cyntec Co., Ltd. (Cyntec)

These notices were required to be lodged in June 2026 for ZYBT and between December 2024 to July 2026 for Cyntec. The delay in lodgement was due to an administrative oversight. Upon becoming aware of the omission, immediate steps to rectify the matter have been taken and have now lodged the notices as soon as practicable.

We apologise for the delay in lodgement and any inconvenience this may have caused.

Should you require any further information or clarification, please do not hesitate to contact us.

Yours Sincerely,

Olga Smejkalova
Secretary

Unit 2.06/31 Lexington Drive, BELLA VISTA, NSW 2153
Ph: 1300 995 098 • www.cambium.bio • ABN 13 127 035 358

## Form 604

Corporations Act 2001
Section 671B

# Notice of change of interests of substantial holder

| | |
|---|---|
| To Company Name/Scheme | **Cambium Bio Limited ("CMB")** |
| ACN/ARSN | **127 035 358** |

### 1. Details of substantial holder (1)

| | |
|---|---|
| Name | **Zheng Yang Biomedical Technology Co., Ltd. ("ZYBT") and Yu-Hung Sebastian Tseng** |
| ACN/ARSN (if applicable) | **N/A** |
| There was a change in the interests of the substantial holder on | **24/07/2026** |
| The previous notice was given to the company on | **24/06/2026** |
| The previous notice was dated | **22/06/2026** |

### 2. Previous and present voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:

| Class of securities (4) | Person's votes – previous notice | Voting power (5) – previous notice | Person's votes – present notice | Voting power (5) – present notice |
|---|---|---|---|---|
| Fully paid ordinary shares (ZYBT) | 10,826,136 | 39.61% | 10,826,136 | 36.78% |
| Fully paid ordinary shares (Yu-Hung Sebastian Tseng) | 454,093 | 1.66% | 454,093 | 1.54% |

### 3. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

| Date of change | Person whose relevant interest changed | Nature of change (6) | Consideration given in relation to change (7) | Class and number of securities affected | Person's votes affected |
|---|---|---|---|---|---|
| 24/07/2026 | Zheng Yang Biomedical Technology Co., Ltd. and Yu-Hung Sebastian Tseng | Dilution of voting power resulting from the issue by the Company of 2,100,000 new fully paid ordinary shares under a placement completed on 24 July 2026, which increased the total number of shares on issue from 27,331,918 to 29,431,918. No change in the number of securities held by the substantial holder or its associate. | N/A | Nil securities of the substantial holder or its associate were affected | ZYBT: 10,826,136 (unchanged); Y-H S Tseng: 454,093 (unchanged) |

### 4. Present relevant interests

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

| Holder of relevant interest | Registered holder of securities | Person entitled to be registered as holder (8) | Nature of relevant interest (6) | Class and number of securities | Person's votes |
|---|---|---|---|---|---|
| Zheng Yang Biomedical Technology Co., Ltd. | Zheng Yang Biomedical Technology Co., Ltd. | Zheng Yang Biomedical Technology Co., Ltd. | Registered holder and beneficial owner | 10,826,136 fully paid ordinary shares | 10,826,136 |
| Yu-Hung Sebastian Tseng | Yu-Hung Sebastian Tseng | Yu-Hung Sebastian Tseng | Registered holder and beneficial owner | 454,093 fully paid ordinary shares | 454,093 |

### 5. Changes in association

The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

| Name and ACN/ARSN (if applicable) | Nature of association |
|---|---|
| N/A | N/A |

### 6. Addresses

The addresses of persons named in this form are as follows:

| Name | Address |
|---|---|
| Zheng Yang Biomedical Technology Co., Ltd. | C/O Sebastian Tseng, 9F NI, 6, KB 83, Sec 1, GuangFu Rd, Sanchong District, New Taipei City, 241 Taiwan |
| Yu-Hung Sebastian Tseng | No 21, Ln 124, Xingyi Rd, Beitou District, Taipei City, 112044, Taiwan |

### Signature

| | |
|---|---|
| print name | **Yu-Hung Sebastian Tseng** |
| capacity | **Chairman of ZYBT** |

sign here Yu-Hung Sebastian Tseng date 8 / 26 / 2026

### DIRECTIONS

(1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 6 of the form.

(2) See the definition of "associate" in section 9 of the Corporations Act 2001.

(3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.

(4) The voting shares of a company constitute one class unless divided into separate classes.

(5) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.

(6) Include details of: (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies). See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.

(7) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.

(8) If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".

(9) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.

## Form 604

Corporations Act 2001

Section 671B

### Notice of change of interests of substantial holder

| | |
|---|---|
| To Company Name/Scheme | **Cambium Bio Limited ("CMB")** |
| ACN/ARSN | **127 035 358** |

**1. Details of substantial holder (1)**

| | |
|---|---|
| Name | **Cyntec Co., Ltd.** |
| ACN/ARSN (if applicable) | **N/A** |
| There was a change in the interests of the substantial holder on | **12/12/2024 and subsequent dates (see section 3)** |
| The previous notice was given to the company on | **04/07/2024** |
| The previous notice was dated | **03/07/2024** |

**2. Previous and present voting power**

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:

| Class of securities (4) | Person's votes – previous notice | Voting power (5) – previous notice | Person's votes – present notice | Voting power (5) – present notice |
|---|---|---|---|---|
| Fully paid ordinary shares | 238,435,861 | 19.99% | 2,384,359 | 8.10% |

**3. Changes in relevant interests**

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

| Date of change | Person whose relevant interest changed | Nature of change (6) | Consideration given in relation to change (7) | Class and number of securities affected | Person's votes affected |
|---|---|---|---|---|---|
| 12/07/2024 | Cyntec Co., Ltd. and Orient EuroPharma Co., Ltd. | Consolidation of the Company's issued capital on the basis that every 100 shares be consolidated into 1 share, as approved by shareholders on 28 June 2024. No change in the substantial holder's proportionate holding. | N/A | 238,435,861 fully paid ordinary shares consolidated into 2,384,359 fully paid ordinary shares | 2,384,359 |
| 12/12/2024 to 24/07/2026 | Cyntec Co., Ltd. and Orient EuroPharma Co., Ltd. | Dilution of voting power resulting from issues of new fully paid ordinary shares by the Company, with no change in the number of securities held by the substantial holder: 1,349,383 shares (12/12/2024); 862,627 shares (13/02/2025); 4,139,650 shares (12/03/2025); 4,570,665 shares (29/08/2025); 114,950 shares (16/10/2025); 4,363,637 shares (17/03/2026); and 2,100,000 shares (24/07/2026). The total number of shares on issue increased from 11,931,006 to 29,431,918. | N/A | Nil securities of the substantial holder or its associate were affected | 2,384,359 (unchanged) |

**4. Present relevant interests**

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

| Holder of relevant interest | Registered holder of securities | Person entitled to be registered as holder (8) | Nature of relevant interest (6) | Class and number of securities | Person's votes |
|---|---|---|---|---|---|
| Cyntec Co., Ltd. | Cyntec Co., Ltd. | Cyntec Co., Ltd. | Registered holder and beneficial owner | 2,384,359 fully paid ordinary shares | 2,384,359 |
| Orient EuroPharma Co., Ltd. | Cyntec Co., Ltd. | Cyntec Co., Ltd. | Indirect relevant interest through 100% ownership of Cyntec Co., Ltd. | 2,384,359 fully paid ordinary shares | 2,384,359 |

**5. Changes in association**

The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

| Name and ACN/ARSN (if applicable) | Nature of association |
|---|---|
| N/A – no change. Orient EuroPharma Co., Ltd. remains an associate as the parent company of Cyntec Co., Ltd. | Control relationship (parent-subsidiary) |

**6. Addresses**

The addresses of persons named in this form are as follows:

| Name | Address |
|---|---|
| Cyntec Co., Ltd. | 13F., No. 128, Sec. 6, Chengde Rd., Taipei 112, Taiwan, R.O.C. |
| Orient EuroPharma Co., Ltd. | 13F., No. 128, Sec. 6, Chengde Rd., Taipei 112, Taiwan, R.O.C. |

**Signature**

| | |
|---|---|
| print name | **TSAI, JING-HONG** |
| capacity | **Director of Cyntec Co., Ltd.** |

sign here Tsai Jing Hong date 26 / 08 / 2026

**DIRECTIONS**

(1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 6 of the form.

(2) See the definition of "associate" in section 9 of the Corporations Act 2001.

(3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.

(4) The voting shares of a company constitute one class unless divided into separate classes.

(5) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.

(6) Include details of: (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies). See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.

(7) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.

(8) If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".

(9) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.